Borssén Åsa D, Palmqvist Richard, Kechagias Stergios, Marschall Hanns-Ulrich, Bergquist Annika, Rorsman Fredrik, Weiland Ola, Verbaan Hans, Nyhlin Nils, Nilsson Emma, Werner Mårten
Department of Public Health and Clinical Medicine Department of Medical Biosciences, Pathology, Umeå University, Umeå Department of Gastroenterology and Hepatology, Department of Medical and Health Sciences, Linköping University, Linköping Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg Department of Medicine, Section of Hepatology and Gastroenterology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm Department of Medical Sciences, Section of Gastroenterology and Hepatology, Uppsala University, Uppsala Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm Gastroenterology Division, Department of Clinical Sciences, Lund University, University Hospital Skane Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Medicine (Baltimore). 2017 Aug;96(34):e7708. doi: 10.1097/MD.0000000000007708.
Autoimmune hepatitis (AIH) is a chronic autoimmune liver disease that if left untreated may lead to the development of cirrhosis. Previous studies on AIH patients have suggested that fibrosis and even cirrhosis can be reversed by medical treatment. The aim of this study was to evaluate the efficacy of medical treatment for protection of developing fibrosis and cirrhosis.A total of 258 liver biopsies from 101 patients (72 women, 29 men) were analyzed by a single pathologist and classified according to the Ishak grading (inflammation) and staging (fibrosis) system. Liver histology was stratified according to the temporal changes of fibrosis stage (increased, decreased, or stable), and groups were compared.Complete or partial response to medical treatment was 94.9%. Reduction of fibrosis stage from the first to the last biopsy was seen in 63 patients (62.4%). We found an association between a reduction in the fibrosis stage and continuous glucocorticoid medication, as well as lowered scores of inflammation at last biopsy. Twenty-one patients had cirrhosis (Ishak stage 6) at least in one of the previous biopsies, but only 5 patients at the last biopsy.Histological improvement is common in AIH patients that respond to medical treatment, and a reduction or stabilization of fibrosis stage occurs in about 2/3 of such patients.
自身免疫性肝炎(AIH)是一种慢性自身免疫性肝病,若不治疗可能会发展为肝硬化。先前针对AIH患者的研究表明,纤维化甚至肝硬化可通过药物治疗得到逆转。本研究的目的是评估药物治疗在预防纤维化和肝硬化发展方面的疗效。
由一名病理学家对101例患者(72名女性,29名男性)的总共258份肝活检样本进行分析,并根据伊沙克分级(炎症)和分期(纤维化)系统进行分类。根据纤维化阶段的时间变化(增加、减少或稳定)对肝脏组织学进行分层,并对各小组进行比较。
药物治疗的完全或部分缓解率为94.9%。63例患者(62.4%)的纤维化阶段从首次活检到最后一次活检有所降低。我们发现纤维化阶段的降低与持续使用糖皮质激素药物以及最后一次活检时炎症评分降低之间存在关联。21例患者在之前至少一次活检中出现肝硬化(伊沙克6期),但在最后一次活检时只有5例。
对药物治疗有反应的AIH患者常见组织学改善,约2/3的此类患者纤维化阶段出现降低或稳定。